home / stock / ymab / ymab news

YMAB News and Press, Y-mAbs Therapeutics Inc.

Stock Information
Company Name: Y-mAbs Therapeutics Inc.
Stock Symbol: YMAB
Market: NASDAQ
Website: ymabs.com
Menu
YMAB YMAB Quote YMAB Short YMAB News YMAB Articles YMAB Message Board
Get YMAB Alerts

News, Short Squeeze, Breakout and More Instantly...
YMAB - How to Take Advantage of moves in (YMAB)

2024-07-05 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
YMAB - Y-mAbs names Peter Pfreundschuh as CFO

2024-07-01 16:14:37 ET More on Y-mAbs Therapeutics Y-mAbs: There's A Ceiling Here Somewhere Y-mAbs Therapeutics, Inc. (YMAB) Q1 2024 Earnings Call Transcript Y-mAbs Therapeutics down 18% as Q1 results disappoint Seeking Alpha’s Quant Rating on Y-mAbs T...

YMAB - Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic pr...

YMAB - ES, SFWL and MOBQ among mid-day movers

2023-05-09 13:22:40 ET Gainers: TScan Therapeutics ( TCRX ) +124% . Shengfeng Development Limited ( SFWL ) +102% . Mobiquity Technologies ( MOBQ ) +68% . ClearOne ( CLRO ) +62% . U.S. GoldMining ( USGOW ) +57% . Novavax ( N...
YMAB - TScan, Ensysce top healthcare gainers; Enanta, Lexaria among losers

2023-05-09 10:00:33 ET Gainers: TScan Therapeutics ( TCRX ) +151% . Ensysce Biosciences ( ENSC ) +60% . Novavax ( NVAX ) +36% . Y-mAbs Therapeutics ( YMAB ) +30% . Longeveron ( LGVN ) +26% . Losers: Enanta Pharmaceuti...

YMAB - ANTRA, ENTA and YMAB are among after hour movers

2023-05-08 18:03:40 ET Gainers: Oportun Financial  ( OPRT ) +23% . EverQuote ( EVER ) +22% . Tactile Systems Technology ( TCMD ) +17% . Rover Group ( ROVR ) +14% . Y-mAbs Therapeutics ( YMAB ) +13% . Losers: Enanta P...

YMAB - Y-mAbs Therapeutics GAAP EPS of -$0.15 beats by $0.17, revenue of $20.25M beats by $4.7M

2023-05-08 16:03:02 ET Y-mAbs Therapeutics press release ( NASDAQ: YMAB ): Q1 GAAP EPS of -$0.15 beats by $0.17 . Revenue of $20.25M (+93.0% Y/Y) beats by $4.7M . Financial Guidance We are updating our full-year 2023 financial guidance, which now reflec...
YMAB - Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance

Q1 2023 DANYELZA® record net product revenues of $20.3 million, driving YoY growth of 93% and a 24% sequential increase compared to Q4 2022 Management updates 2023 financial guidance, now anticipating higher DANYELZA net revenues of $80-85 million and lower cash burn of $40-50 millio...

YMAB - Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023

NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended March 31, 2023, on Monday, May 8, 2023, after the close of the U.S. financi...

YMAB - Y-mAbs Announces Presentation of Naxitamab data at AACR

NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatme...
Next 10